2019
DOI: 10.1063/1.5092803
|View full text |Cite
|
Sign up to set email alerts
|

Structural and dynamical description of the enzymatic reaction of a phosphohexomutase

Abstract: Enzymes are known to adopt various conformations at different points along their catalytic cycles. Here, we present a comprehensive analysis of 15 isomorphous, high resolution crystal structures of the enzyme phosphoglucomutase from the bacterium Xanthomonas citri . The protein was captured in distinct states critical to function, including enzyme-substrate, enzyme-product, and enzyme-intermediate complexes. Key residues in ligand recognition and regions undergoing conformational change … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 60 publications
0
6
1
Order By: Relevance
“…It is less clear from available structures (present results and in Stiers et al 24 and references cited therein) why the PMM/PGMs have roughly the same activity on both α-d-mannose and α-d-glucose 1-phosphate substrates, while the PGMs have an activity that is several orders of magnitude higher for the latter 7,32 . Firstly, in the X. citri PMM/PGM:G1P complex there is an Arg residue interacting with hydroxyls both at C2 and C3 24 , but this residue is not conserved in metazoan PGMs. It is therefore not a universal axial C2-hydroxyl "reader", and in our human PGM1-2:G1P complex there are no residues interacting directly with the C2 hydroxyl.…”
Section: Resultscontrasting
confidence: 55%
See 2 more Smart Citations
“…It is less clear from available structures (present results and in Stiers et al 24 and references cited therein) why the PMM/PGMs have roughly the same activity on both α-d-mannose and α-d-glucose 1-phosphate substrates, while the PGMs have an activity that is several orders of magnitude higher for the latter 7,32 . Firstly, in the X. citri PMM/PGM:G1P complex there is an Arg residue interacting with hydroxyls both at C2 and C3 24 , but this residue is not conserved in metazoan PGMs. It is therefore not a universal axial C2-hydroxyl "reader", and in our human PGM1-2:G1P complex there are no residues interacting directly with the C2 hydroxyl.…”
Section: Resultscontrasting
confidence: 55%
“…Only minor differences can be seen when comparing the free protein structure with the complex structures, with D4 rotated 2° or www.nature.com/scientificreports www.nature.com/scientificreports/ less in the complexes, compared to the free protein structure. Similarly, in a recent study of complex structures and free protein for a bacterial phosphoglucomutase 24 conformational variability was not observed for D4. It was speculated that this might be due to tight packing in the crystal lattice.…”
Section: Resultsmentioning
confidence: 75%
See 1 more Smart Citation
“…PCA has been proved to detect conformational differences in protein structures, which ultimately correlate to functional activities ( 31 ). PCA was recently applied to get insights into the conformational ensembles and space sampling of GroEL ( 32 ), heterotrimeric G proteins ( 33 ), and Xanthomonas citri phosphohexomutase structures ( 34 ). Hence, PCA was performed on the best-fit structural alignment of all our structures; as a result, the first three PCs accounted for 98% of the total variance ( Fig.…”
Section: Discussionmentioning
confidence: 99%
“…Working on a single crystal is marginally useful to understanding the enzyme movements during the catalytic process and to plan possible molecular structures interacting or interfering with different conformational states of the enzyme. At the moment, it is possible to combine different crystal snapshots to have an idea of the enzyme conformational changes during the catalytic process, as it was performed for the ubiquitous enzymes α-D-phosphohexomutases [23].…”
Section: From Hit To Lead: Structure-guided Drug Design and Beyondmentioning
confidence: 99%